POSTERIORPITUITARYHARMONES 319FURTHER READING
Birnbaumer M. Vasopressin receptors. Trends in Endocrinology and
Metabolism2000; 11 : 406–10.
Drolet G, Rivest S. Corticotropin-releasing hormone and its receptors; an
evaluation at the transcription level in vivo. Peptides2001; 22 : 761–7.
Feenstra J, de Herder WW, ten Have SM et al. Combined therapy with
somatostatin analogues and weekly pegvisomant in active
acromegaly. Lancet2005; 365 : 1644–6.
Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure,
function and regulation of secretion. Physiological Research2000; 80 :
1524–85.
Hays RM. Vasopressin antagonists – progress and promise. New
England Journal of Medicine2006; 355 : 2146–8.
Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ. 1996
Octreotide. New England Journal of Medicine1996; 334 : 246–54.
Melmed S. Medical progress: acromegaly. New England Journal of
Medicine2006; 355 : 2558–73.
Okada S, Kopchick JJ. Biological effects of growth hormone and its
antagonist.Trends in Molecular Medicine2001; 7 : 126–32.
Thibonnier M, Coles P, Thibonnier A et al. 2001 The basic and clinical
pharmacology of nonpeptide vasopressin receptor antagonists.
Annual Review of Pharmacology2001; 41 : 175–202.
Trainer PJ, Drake WM, Katznelson L et al. Treatment of acromegaly
with the growth hormone-receptor antagonist pegvisomant. New
England Journal of Medicine2000; 342 : 1171–7.
Vance ML, Mauras N. Growth hormone therapy in adults and chil-
dren. New England Journal of Medicine1999; 341 : 1206–16.
Wenzel V, Krismer AC, Arntz HR et al. A comparison of vasopressin
and epinephrine for out-of-hospital cardiopulmonary resuscita-
tion.New England Journal of Medicine2004; 350 : 105–13.